BridgeBio gears up for FDA review of acoramidis following Phase III results

Submitted by admin on January 11, 2024 - 11:07am

Source:

Clinical Trials Arena

News Tags:

Headline:

snippet:

BridgeBio submitted the NDA with US FDA for the TTR stabiliser in December 2023 and plans to engage with other regulatory bodies this year.

Search form